Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
Provided By GlobeNewswire
Last update: May 8, 2024
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials
Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients
Read more at globenewswire.com
